Table 3. Treatment Outcomes.
LT: Lung Transplant; SL: Single Lung; BL: Bilateral Lung; HL: Heart and Lung; RI: Reduction in immunosuppression; CHOP: cyclophosphamide, hydroxyrubicin, vincristine, prednisone; R-CHOP: rixtuximab, cyclophosphamide, hydroxyrubicin, vincristine, prednisone; M: Male; F: Female
| Age | Sex | Type of LT | Treatment | Response at end of Treatment | Outcome at End of Study |
|---|---|---|---|---|---|
| 22 | - | BL | RI | Remission | Dead |
| 47 | - | BL | RI | Remission | Dead |
| 61 | - | SL | None | - | Dead |
| 24 | - | BL | RI | Remission | Dead |
| 55 | - | BL | RI + Chemotherapy | No response | Dead |
| 51 | - | HL | RI | Remission | Dead |
| 46 | - | BL | RI + Chemotherapy | No response | Dead |
| 58 | - | SL | RI + Chemotherapy | No response | Dead |
| 46 | - | BL | None | - | Dead |
| 28 | - | BL | RI | Remission | Dead |
| 61 | - | BL | RI | No Response | Dead |
| 52 | - | BL | RI + Chemotherapy | Remission | Dead |
| 57 | - | SL | RI | Remission | Dead |
| 60 | - | BL | RI | Regression | Dead |
| 36 | - | BL | RI + Interferon Alpha | Remission | Dead |
| 52 | - | BSL | RI + Chemotherapy | Remission | Dead |
| 49 | - | BL | RI | Remission | Dead |
| 32 | - | SL | RI + Chemotherapy | No Response | Dead |
| 58 | - | SL | RI | Remission | Dead |
| 32 | - | SL | RI + Complete Resection + Chemotherapy | Remission | Dead |
| 60 | - | SL | RI | No Response | Dead |
| 40 | - | BL | RI + Chemotherapy | No Response | Dead |
| 52 | - | SL | RI + Incomplete Resection | No Response | Dead |
| 52 | - | SL | None | No Response | Dead |
| 52 | - | SL | RI + Incomplete Resection | No Response | Dead |
| 54 | - | SL | RI + Complete Resection | Remission | Dead |
| 59 | - | SL | RI | - | Dead |
| 51 | - | BL | RI | Remission | Dead |
| 52 | - | BL | RI | Remission | Dead |
| 60 | - | SL | RI + Incomplete Resection | No Response | Dead |
| 11 | F | HL | RI + Ritux | Remission | Dead |
| 21 | F | BL | RI + Ritux | Progressive Disease | Alive |
| M | SL | RI + Surgery | Remission | Dead | |
| 63 | M | SL | RI + Acyclovir | Remission | Dead |
| 60 | F | SL | RI + R-CHOP | Remission | Dead |
| 53 | F | SL | RI + R-CHOP | Remission | Dead |
| 26 | F | SL | RI +CHOP | Progressive Disease | Dead |
| 53 | M | SL | RI + GMALL 2002+Ritux | Remission | Dead |
| 52 | M | SL | RI + R-CHOP | Remission | Alive |
| 15 | M | HL | RI + CHOP | Remission | Dead |
| 39 | M | BL | RI+ CHOP + rituximab | Progressive Disease | Dead |
| 24 | F | BL | RI + CHOP + rituximab | No Response | Dead |
| 52 | M | SL | RIS + CHOP + rituximab | No Response | Dead |
| 26 | M | BL | Interferon + rituximab | No Response | Alive |
| 29 | M | BL | RI+ rituximab + Chemotherapy | Remission | Alive |
| 44 | F | BL | RI + rituximab | Remission | Dead |
| 30 | M | BL | RI + rituximab | Remission | Dead |
| 51 | M | HL | RI + rituximab | Remission | Dead |
| 32 | M | HL | RI + rituximab | Remission | Dead |
| 56 | M | HL | rituximab Clinical Trial | No Response | Dead |
| 60 | F | - | rituximab | Remission | Dead |
| 52 | F | - | rituximab | Relapse | Alive |
| 57 | F | - | rituximab | Remission | Dead |
| 73 | M | - | rituximab | Progressive Disease | Dead |
| 34 | F | - | rituximab | Remission | Alive |